Down syndrome suppression of tumor growth and the role of the calcineurin inhibitor DSCR1

The incidence of many cancer types is significantly reduced in individuals with Down’s syndrome, and it is thought that this broad cancer protection is conferred by the increased expression of one or more of the 231 supernumerary genes on the extra copy of chromosome 21. One such gene is Down’s syndrome candidate region-1 (DSCR1, also known as RCAN1), which encodes a protein that suppresses vascular endothelial growth factor (VEGF)-mediated angiogenic signalling by the calcineurin pathway. Here we show that DSCR1 is increased in Down’s syndrome tissues and in a mouse model of Down’s syndrome. Furthermore, we show that the modest increase in expression afforded by a single extra transgenic copy of Dscr1 is sufficient to confer significant suppression of tumour growth in mice, and that such resistance is a consequence of a deficit in tumour angiogenesis arising from suppression of the calcineurin pathway. We also provide evidence that attenuation of calcineurin activity by DSCR1, together with another chromosome 21 gene Dyrk1a, may be sufficient to markedly diminish angiogenesis. These data provide a mechanism for the reduced cancer incidence in Down’s syndrome and identify the calcineurin signalling pathway, and its regulators DSCR1 and DYRK1A, as potential therapeutic targets in cancers arising in all individuals.

[1]  C. Fletcher,et al.  Down's syndrome: an atheroma-free model? , 1977, British medical journal.

[2]  R. Bronson,et al.  A mouse model for Down syndrome exhibits learning and behaviour deficits , 1995, Nature Genetics.

[3]  Y. Gwack,et al.  A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT , 2006, Nature.

[4]  Michael C. Ostrowski,et al.  Trisomy represses ApcMin-mediated tumours in mouse models of Down’s syndrome , 2008, Nature.

[5]  C. Epstein,et al.  The mapping of transgenes by fluorescence in situ hybridization on G-banded mouse chromosomes , 1994, Mammalian Genome.

[6]  T. Fulcher,et al.  Diabetic retinopathy in Down’s syndrome , 1998, The British journal of ophthalmology.

[7]  Lei Yuan,et al.  Engineering Robust and Functional Vascular Networks In Vivo With Human Adult and Cord Blood–Derived Progenitor Cells , 2008, Circulation research.

[8]  George Q. Daley,et al.  Disease-Specific Induced Pluripotent Stem Cells , 2008, Cell.

[9]  F. McKeon,et al.  The threshold pattern of calcineurin-dependent gene expression is altered by loss of the endogenous inhibitor calcipressin , 2003, Nature Immunology.

[10]  Eero Pukkala,et al.  Cancer incidence of persons with down syndrome in Finland: A population‐based study , 2006, International journal of cancer.

[11]  N. Maeda,et al.  Single-copy transgenic mice with chosen-site integration. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[12]  W. Kamps,et al.  A lack of neuroblastoma in Down syndrome: a study from 11 European countries. , 1998, Cancer research.

[13]  W C Black,et al.  Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. , 1993, The New England journal of medicine.

[14]  E. Olson,et al.  Independent Signals Control Expression of the Calcineurin Inhibitory Proteins MCIP1 and MCIP2 in Striated Muscles , 2000, Circulation research.

[15]  Stuart L. Schreiber,et al.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.

[16]  J. Redondo,et al.  Selective Inhibition of Vascular Endothelial Growth Factor–Mediated Angiogenesis by Cyclosporin a , 2001, The Journal of experimental medicine.

[17]  S. Rasmussen,et al.  Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study , 2002, The Lancet.

[18]  E. Passegué,et al.  Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch , 2006, Proceedings of the National Academy of Sciences.

[19]  Takahide Kohro,et al.  Vascular Endothelial Growth Factor- and Thrombin-induced Termination Factor, Down Syndrome Critical Region-1, Attenuates Endothelial Cell Proliferation and Angiogenesis*♦ , 2004, Journal of Biological Chemistry.

[20]  Masashi Iizuka,et al.  Down Syndrome Candidate Region 1,a Downstream Target of VEGF, Participa tes in Endothelial Cell Migration and Angiogenesis , 2004, Journal of Vascular Research.

[21]  鮫島 浩,et al.  Population-based study からみた神経予後不良因子の検討 , 2009 .

[22]  J. McPherson,et al.  A Chromosome 21 Critical Region Does Not Cause Specific Down Syndrome Phenotypes , 2022 .

[23]  D. Jacobowitz,et al.  Elevated Expression of the G-Protein-Activated Inwardly Rectifying Potassium Channel 2 (GIRK2) in Cerebellar Unipolar Brush Cells of a Down Syndrome Mouse Model , 2006, Cellular and Molecular Neurobiology.

[24]  Xin Gao,et al.  NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21 , 2006, Nature.

[25]  Napoleone Ferrara,et al.  Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. , 2004, Blood.

[26]  J. Soulillou,et al.  Immunosuppressive drugs and the risk of cancer after organ transplantation. , 2005, The New England journal of medicine.

[27]  H. Hasle,et al.  Risks of leukaemia and solid tumours in individuals with Down's syndrome , 2000, The Lancet.

[28]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[29]  X. Estivill,et al.  Genomic organization, alternative splicing, and expression patterns of the DSCR1 (Down syndrome candidate region 1) gene. , 1997, Genomics.

[30]  E. Duh,et al.  VEGF selectively induces Down syndrome critical region 1 gene expression in endothelial cells: a mechanism for feedback regulation of angiogenesis? , 2004, Biochemical and biophysical research communications.

[31]  F. McKeon,et al.  Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. , 2008, Cancer cell.